{"id":"W4224750762","doi":"10.1007/s43441-022-00409-w","title":"Global Regulatory and Public Health Initiatives to Advance Pediatric Drug Development for Rare Diseases","year":2022,"lang":"en","type":"review","venue":"Therapeutic Innovation & Regulatory Science","topic":"CRISPR and Genetic Engineering","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Canada","funders":"National Center for Advancing Translational Sciences; Rare Diseases Clinical Research Network; National Institutes of Health; Ministry of Health, Labour and Welfare; Patient-Centered Outcomes Research Institute; National Organization for Rare Disorders","keywords":"Drug development; Medicine; Clinical trial; Pharmacy; Orphan drug; Pandemic; Public health; Disease; Population; Intensive care medicine; Business; Drug; Family medicine; Environmental health; Coronavirus disease 2019 (COVID-19); Infectious disease (medical specialty); Nursing; Pharmacology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006555502,0.0009969671,0.000905293,0.002718481,0.000544842,0.002258485,0.001497312,0.003750572,0.007843994],"category_scores_gemma":[0.00605038,0.0003293771,0.0009653994,0.002798181,0.001859952,0.003870589,0.002037746,0.006991718,0.00246095],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002623676,"about_ca_system_score_gemma":0.008297941,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001771364,"about_ca_topic_score_gemma":0.002314198,"domain_scores_codex":[0.9983808,0.0004720381,0.0001490175,0.000193624,0.0005994581,0.0002050092],"domain_scores_gemma":[0.9939016,0.003597534,0.000552761,0.0001994733,0.001245445,0.000503214],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00003965133,0.0001046249,0.0002138604,0.00916379,0.00006107541,0.0001962426,0.0001635282,0.0008635229,0.001260694,0.05900506,0.1049729,0.8239551],"study_design_scores_gemma":[0.00001035954,0.0000442765,0.0002095312,0.002622733,0.00002142728,0.0003012471,0.00005334418,0.00005288117,0.0002492279,0.004739415,0.9916858,0.000009828723],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002083862,0.9692301,0.001507594,0.01570782,0.002109759,0.00003620042,0.00007364067,0.00009007246,0.01103657],"genre_scores_gemma":[0.002094448,0.983803,0.002370247,0.008456391,0.001041025,0.00004201439,0.0001079742,0.00001912996,0.002065841],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.007843994,"threshold_uncertainty_score":0.03466922,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04255516405409542,"score_gpt":0.3741790676218467,"score_spread":0.3316239035677513,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}